Muhammad Furqan

7PUBLICATIONS
59CO-AUTHORS
Tumour immunologyCommercial lawInnate immunityMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 12, 2025
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.

Zev A Wainberg, Colin D Weekes, Muhammad Furqan

|May 01, 2025
Safety and Tolerability of Lete-cel in NSCLC-Reply.

Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann

|Dec 13, 2024
Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.

Muhammad Furqan, Jyoti Malhotra, Ardaman Shergill

|Nov 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.

Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann

|Sep 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.

Daniel Morgensztern, Neal Ready, Melissa L Johnson

|Apr 17, 2024
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.

Muhammad Furqan, Siddharth Karanth, Ravi K Goyal

Pageof 2

Frequent Collaborators

2 joint publications

Ramaswamy Govindan

2 joint publications

Jennifer W Carlisle

2 joint publications

Martin J Edelman

2 joint publications

Liza C Villaruz